Amatuximab

Last updated
Amatuximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target mesothelin
Clinical data
Other namesMORAb-009
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6394H9870N1694O2024S46
Molar mass 144331.89 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. [1] It was developed by Morphotek, Inc.

Contents

Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing. [2] [3]

Intellectual property

In December 2005 Morphotek signed an exclusive license agreement for MORAb-009 with the National Cancer Institute. Quickly following they opened an Investigational New Drug Application with the FDA in 2006 and initiated Phase I clinical trials. [4] In November 2010, Morphotek (now as an acquisition of Eisai Co. Ltd.) entered a Sponsored Research Agreement (SRA) with Hokkaido University in Sapporo, Japan to perform studies evaluating the use of amatuximab in advanced pancreatic cancer. [5] Specifically, the study was investigating the anti-tumor effect of amatuximab as a single agent as well as in combination with gemcitabine. [6] The FDA granted amatuximab orphan drug status for use in malignant pleural mesothelioma in November 2012, and the European Commission soon followed granting orphan drug status in January 2014. [4]

Manufacturer financials

Morphotek was founded in the year 2000 by Dr. Nicholas Nicolaides, Dr. Philip Sass, and Dr. Luigi Grasso out of Exton, Pennsylvania. The primary focus of the company is development of biological drug products for the treatment of inflammatory disease, cancer, and infectious disease. In 2007 Morphotek was acquired by the pharmaceutical company Eisai and now functions as a subsidiary of Eisai. [7] The annual net income growth of Eisai in the 2017 fiscal year was -28.35%, its sales and revenue growth -1.61%, and overall EBITDA 77.69 B. Within the capital structure of Eisai, their long-term debt to equity is 28.35 and long-term debt to total capital is 20.71. Finally, their profitability gross margin was 61.42 this past fiscal year. [8]

Clinical trials

To date there have been seven Phase I and Phase II clinical trials; four Phase I trials and three Phase II trials. [9] The first Phase I clinical trial "A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects with Advanced Mesothelin-expressing Tumors" started in May 2006 with 24 enrolled participants and concluded in September 2008. No results have been posted. [10] One of the early Phase I trials "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers" started in July 2013 with seven enrolled participants and was terminated early in November 2013. This clinical trial was the only trial not sponsored by Morphotek or Eisai but by the National Cancer Institute (NCI). [11] However, Morphotek had just completed a similar Phase I trial just prior in March 2013. The results of this study have not been posted. [12] Two of the Phase II trials are complete. "A Phase II Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-099 in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer" was completed in 2009 and has posted results. The study enrolled 155 participants and no participants in either the experimental or placebo group completed the trial due primarily to lack of efficacy. Further, the results examined prior to the dis-enrollment of participants concluded that the median primary outcomes measure, overall survival measured in months from the time of randomization, did not increase in the MORAb-099 plus gemcitabine group compared to the placebo plus gemcitabine group. [13] The final Phase II trial "A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma" was started in November 2015 with 108 enrolled participants and is estimated to be completed in September 2018. [14] No Phase III trials have been started.

Related Research Articles

<span class="mw-page-title-main">Mesothelioma</span> Cancer associated with asbestos

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs. The area most commonly affected is the lining of the lungs and chest wall. Less commonly the lining of the abdomen and rarely the sac surrounding the heart, or the sac surrounding the testis may be affected. Signs and symptoms of mesothelioma may include shortness of breath due to fluid around the lung, a swollen abdomen, chest wall pain, cough, feeling tired, and weight loss. These symptoms typically come on slowly.

<span class="mw-page-title-main">Pemetrexed</span> Chemical compound

Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

<span class="mw-page-title-main">Mesothelin</span> Protein found in humans

Mesothelin, also known as MSLN, is a protein that in humans is encoded by the MSLN gene.

An anti-CD22 immunotoxin is a monoclonal antibody linked to a cytotoxic agent. They are being studied in the treatment of some types of B-cell cancer.

Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody of IgG1/κ which is being investigated for the treatment of ovarian cancer.

<span class="mw-page-title-main">Nivolumab</span> Cancer drug

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein.

Demcizumab is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.

Zolbetuximab is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. Astellas Pharmaceuticals acquired the rights to Zolbetuximab in December, 2016 when it acquired Ganymed Pharmaceuticals.

<span class="mw-page-title-main">Durvalumab</span> Pharmaceutical drug

Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

<span class="mw-page-title-main">Atezolizumab</span> Monoclonal anti-PD-L1 antibody

Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

Ieramilimab is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998.

<span class="mw-page-title-main">Halozyme</span> Biotechnology company

Halozyme Therapeutics is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion. The most common side effects of lecanemab include headache, infusion-related reactions and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid.

<span class="mw-page-title-main">Trastuzumab deruxtecan</span> Medication

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized by the cell, carrying the bound deruxtecan along with it, where it interferes with the cell's ability to make DNA structural changes and replicate its DNA during cell division, leading to DNA damage when the cell attempts to replicate itself, destroying the cell.

Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma. Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor.

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab" (PDF). American Medical Association.
  2. ↑ Baas HI, Hassan R, Nowak AK, Rice D (2018). "Chapter 53: Malignant mesothelioma.". In Pass HI, Ball D, Scagliotti GV (eds.). IASLC Thoracic Oncology (2nd ed.). Elsevier. pp. 536–549.e4. doi:10.1016/B978-0-323-52357-8.00053-6. ISBN   978-0-323-52357-8.
  3. ↑ Baldo P, Cecco S (2017). "Amatuximab and novel agents targeting mesothelin for solid tumors". OncoTargets and Therapy. 10: 5337–5353. doi: 10.2147/OTT.S145105 . PMC   5687483 . PMID   29184420.
  4. 1 2 "History". Morphotek. Archived from the original on 7 November 2017. Retrieved 1 November 2017.
  5. ↑ "Morphotek®, Inc. Announces Initiation of a Sponsored Research Agreement (SRA) with Hokkaido University to Evaluate Amatuximab (MORAb-009) in Advanced Pancreatic Cancer". Business Wire. 17 November 2010. Retrieved 1 November 2017.
  6. ↑ "Morphotek, Inc. Announces Initiation of A Sponsored Research Agreement with Hokkaido University to Evaluate Amatuximab (MORAb-009) in Advanced Pancreatic Cancer". Morphotek. Archived from the original on 7 November 2017. Retrieved 1 November 2017.
  7. ↑ "About Morphotek". Morphotek. Archived from the original on 1 November 2017. Retrieved 1 November 2017.
  8. ↑ "Eisai Co. Ltd". The Wall Street Journal. 1 November 2017. Retrieved 1 November 2017.
  9. ↑ "Amatuximab". ClinicalTrials.gov. U.S. National Library of Medicine. Retrieved 1 November 2017.
  10. ↑ Clinical trial number NCT00325494 for "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer" at ClinicalTrials.gov
  11. ↑ Clinical trial number NCT01413451 for "Amatuximab for High Mesothelin Cancers" at ClinicalTrials.gov
  12. ↑ Clinical trial number NCT01521325 for "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers" at ClinicalTrials.gov
  13. ↑ Clinical trial number NCT00570713 for "An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer" at ClinicalTrials.gov
  14. ↑ Clinical trial number NCT02357147 for "Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS)" at ClinicalTrials.gov
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.